Equities research analysts at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Lipocine Price Performance
Shares of NASDAQ LPCN opened at $4.81 on Friday. Lipocine has a 1 year low of $2.31 and a 1 year high of $7.15. The company’s 50-day moving average is $4.58 and its 200 day moving average is $3.56. The stock has a market capitalization of $25.73 million, a P/E ratio of -1.58 and a beta of 1.05.
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.11. The company had revenue of $0.22 million for the quarter. Research analysts anticipate that Lipocine will post -1.49 earnings per share for the current year.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Read More
- Five stocks we like better than Lipocine
- ESG Stocks, What Investors Should Know
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How to Invest in Blue Chip Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
